6 unknown. 6 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Unknown 6 |
| Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Antineoplastic Agents: new trials by email Literature Review of Antineoplastic Agents trials Research Report on Antineoplastic Agents
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma Nivolumab Injection [Opdivo] - Neoplasms, Carcinoma, Squamous | Phase 2 | Unknown | The First Affiliated Hospital of Guangzhou Medical University | 25 | 2023-10-01 | 2024-05-21 |
| Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma Anlotinib, Cisplatin, Carboplatin - Urothelial Carcinoma, Anlotinib | Phase 2 | Unknown | Tianjin Medical University Second Hospital | 53 | 2021-10-01 | 2021-09-01 |
| Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01) tislelizumab and BCG - Urinary Bladder Neoplasms, Urologic Neoplasms | Phase 1 / Phase 2 | Unknown | RenJi Hospital | 6 | 2021-06-01 | 2021-06-11 |
| Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer Niraparib, Bevacizumab - Ovarian Neoplasms, Fallopian Tube Neoplasms | Phase 2 | Unknown | Xiaoxiang Chen | 32 | 2020-11-06 | 2020-11-10 |
| Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Anlotinib, Olaparib - Ovarian Cancer, Ovarian and Fallopian Tube Cysts and Neoplasms | Phase 2 | Unknown | Xiaoxiang Chen | 68 | 2020-10-28 | 2020-10-30 |
| Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer. Palonosetron, Ondansetron - Breast Neoplasm, Antineoplastic Agents | Phase 2 / Phase 3 | Unknown | Instituto Nacional de Cancerologia de Mexico | 560 | 2015-11-05 | 2018-07-30 |
Urogenital Neoplasms (4) · Neoplasms (3) · Adnexal Diseases (2) · Carcinoma (2) · Carcinoma, Ovarian Epithelial (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Ovarian Diseases (2) · Ovarian Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Squamous Cell (1) · Carcinoma, Transitional Cell (1)
Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Male Urogenital Diseases (4) · Neoplasms by Site (4) · Urogenital Diseases (4) · Neoplasms (3) · Carcinoma (2) · Genital Diseases (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Breast Diseases (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Fallopian Tube Diseases (1) · Gonadal Disorders (1)
Carboplatin (2) · anlotinib (2) · Bevacizumab (1) · Cisplatin (1) · Gemcitabine (1) · Nivolumab (1) · Ondansetron (1) · Paclitaxel (1) · Palonosetron (1) · niraparib (1) · olaparib (1) · tislelizumab (1)
Xiaoxiang Chen (2) · Instituto Nacional de Cancerologia de Mexico (1) · RenJi Hospital (1) · The First Affiliated Hospital of Guangzhou Medical University (1) · Tianjin Medical University Second Hospital (1)
China (5) · Mexico (1)
Xiaoxiang Chen, MD,PhD (2) · Claudia H Arce Salinas, MD (1) · Shuben Li, PhD (1) · Yuanjie Niu, MD,PhD (1)
PMID 11226762, PMID 12686700, PMID 12697943, PMID 1352024, PMID 15139073, PMID 16766588, PMID 17187507, PMID 17530482, PMID 18525044, PMID 19037667, PMID 20972805, PMID 21533811, PMID 22488022, PMID 23358260, PMID 24761161, PMID 25012726, PMID 25106522, PMID 3281702, PMID 3544842, PMID 6681766, PMID 9789602